tiprankstipranks
Trending News
More News >
Elicio Therapeutics, Inc (ELTX)
:ELTX

Elicio Therapeutics (ELTX) Stock Statistics & Valuation Metrics

Compare
199 Followers

Total Valuation

Elicio Therapeutics has a market cap or net worth of $129.26M. The enterprise value is $77.98M.
Market Cap$129.26M
Enterprise Value$77.98M

Share Statistics

Elicio Therapeutics has 15,996,976 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,996,976
Owned by Insiders35.05%
Owned by Institutions5.58%

Financial Efficiency

Elicio Therapeutics’s return on equity (ROE) is 4.59 and return on invested capital (ROIC) is -243.73%.
Return on Equity (ROE)4.59
Return on Assets (ROA)-1.84
Return on Invested Capital (ROIC)-243.73%
Return on Capital Employed (ROCE)-2.70
Revenue Per Employee0.00
Profits Per Employee-1.62M
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Elicio Therapeutics is -1.20. Elicio Therapeutics’s PEG ratio is -0.22.
PE Ratio-1.20
PS Ratio0.00
PB Ratio8.23
Price to Fair Value-5.50
Price to FCF-2.36
Price to Operating Cash Flow-2.09
PEG Ratio-0.22

Income Statement

In the last 12 months, Elicio Therapeutics had revenue of 0.00 and earned -51.90M in profits. Earnings per share was -4.25.
Revenue0.00
Gross Profit0.00
Operating Income-44.99M
Pretax Income-51.90M
Net Income-51.90M
EBITDA-50.27M
Earnings Per Share (EPS)-4.25

Cash Flow

In the last 12 months, operating cash flow was -35.06M and capital expenditures -129.00K, giving a free cash flow of -38.30M billion.
Operating Cash Flow-35.06M
Free Cash Flow-38.30M
Free Cash Flow per Share-2.39

Dividends & Yields

Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.66
52-Week Price Change0.25%
50-Day Moving Average5.79
200-Day Moving Average5.84
Relative Strength Index (RSI)70.98
Average Volume (3m)39.16K

Important Dates

Elicio Therapeutics upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date

Financial Position

Elicio Therapeutics as a current ratio of 1.80, with Debt / Equity ratio of 65.04%
Current Ratio1.80
Quick Ratio1.80
Debt to Market Cap0.34
Net Debt to EBITDA-0.17
Interest Coverage Ratio-98.87

Taxes

In the past 12 months, Elicio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Elicio Therapeutics EV to EBITDA ratio is -1.41, with an EV/FCF ratio of -1.90.
EV to Sales0.00
EV to EBITDA-1.41
EV to Free Cash Flow-1.90
EV to Operating Cash Flow-1.91

Balance Sheet

Elicio Therapeutics has $18.35M in cash and marketable securities with $5.79M in debt, giving a net cash position of -$12.56M billion.
Cash & Marketable Securities$18.35M
Total Debt$5.79M
Net Cash-$12.56M
Net Cash Per Share-$0.79
Tangible Book Value Per Share-$0.93

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Elicio Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside35.80% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast27.65%

Scores

Smart Score5
AI Score30.25
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis